Kenji Nakahama

Dr. Kenji Nakahama


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2022 in Thoracic Cancer
Verified
Journal Article
Open access
KNKenji Nakahama
Kenji Nakahama
HKHiroyasu Kaneda
Hiroyasu Kaneda
MOMasahiko Osawa
Masahiko Osawa
MIMotohiro Izumi
Motohiro Izumi
NYNaoki Yoshimoto
Naoki Yoshimoto
TKTomoya Kawaguchi
Tomoya Kawaguchi
Background: We aimed to identify the relationship between thyroid transcription factor‐1 (TTF‐1) expression of lung adenocarcinoma and the efficacy of immune‐checkpoint inhibitor (ICI) therapy.Methods: This retrospective multicenter study comprised patients with advanced lung adenocarcinoma treated with ICI monotherapy. We collected clinical medical records including data on TTF‐1 expression and analyzed the relationship between TTF‐1 expression and programmed death‐ligand 1 tumor proportion score (PD‐L1 TPS), objective response rate (ORR), progression‐free survival (PFS), and overall survival (OS).Results: In total, 108 patients with lung adenocarcinoma were analyzed. The rate of TPS ≥1% and ≥50% in patients with positive TTF‐1 expression was significantly higher than that in patients with negative TTF‐1 expression (88% vs. 60%, p < 0.001; 65% vs. 24%, p < 0.001). The ORR was significantly higher in TTF‐1 positive patients than in TTF‐1‐negative patients (38% vs. 8%, p = 0.003). Among patients with TPS ≥50% and 1%–49%, the ORR in TTF‐1 positive and negative patients was 48% (26/54) versus 17% (1/6) (p = 0.21), and 32% (6/19) versus 11% (1/9) (p = 0.37), respectively. The ORR for patients with TPS <1% was 0% in both the TTF‐1 negative and positive cases. The median PFS and OS was significantly longer in TTF‐1‐positive patients than in TTF‐1‐negative patients (5.4 vs. 1.6 months, p < 0.001; 18.2 vs. 8.0 months, p = 0.041). Multivariate analysis revealed that TTF‐1‐negative status was an independent unfavorable prognostic factor for PFS.Conclusion: Patients with TTF‐1‐positive status receiving ICI monotherapy showed better outcomes than those with TTF‐1‐negative lung adenocarcinoma.

1 July 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
MTMotohiro Tamiya
Motohiro Tamiya
ATAkihiro Tamiya
Akihiro Tamiya
HSHidekazu Suzuki
Hidekazu Suzuki
KMKazunori Moriizumi
Kazunori Moriizumi
KNKenji Nakahama
Kenji Nakahama
TKToru Kumagai
Toru Kumagai
Background/Aim: Treatment with EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring EGFR mutation; however, treatment resistance occurs within 1-1.5 years following first-line EGFR-TKIs [first- and second-generation (G) TKIs]. When resistant NSCLC exhibits T790M mutations, osimertinib is the standard therapy. However, intratumoral heterogeneity and clonal evolution may occur in NSCLC. Afatinib may overcome tumor heterogeneity, leading to T790M colonal purity. We aimed to determine whether NSCLC treatment with afatinib followed by osimertinib (afatinib group) provides higher therapeutic efficacy than other 1st-G EFGR-TKIs followed by osimertinib (1st-G group). Materials and Methods: This multicenter retrospective study evaluated outcomes between afatinib group and 1st-G group. We analyzed clinical data from NSCLC patients receiving osimertinib after progression following 1st- or 2nd-G EGFR-TKIs between March 28, 2016 and March 31, 2018. Patients with performance status (PS) 0-2 were enrolled to reduce bias of patients' conditions. Results: We enrolled 111 patients treated with osimertinib. The median age was 69 (range: 39-88) years. Out of 111 patients, 33 (29.7%) were men, 100 (90%) had PS 0-1, and 35 (31.5%) were in the afatinib group. The objective RR and DCR were significantly higher in the afatinib group than in the 1st-G group [82.9% vs. 53.9% (p=0.0065); 91.4% vs. 71.1% (p=0.032)]. The median PFS tended higher in the afatinib group than in the 1st-G group (15.6 vs. 8.9 months, p=0.195). Conclusion: Afatinib followed by osimertinib may provide better outcomes for T790M-positive NSCLC than 1st-G EGFR-TKIs. Afatinib followed by osimertinib may be a therapeutic option for NSCLC harboring EGFR mutation.

1 December 2017 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KNKenji Nakahama
Kenji Nakahama
ATAkihiro Tamiya
Akihiro Tamiya
YTYoshihiko Taniguchi
Yoshihiko Taniguchi
YSYumiko Sasaki
Yumiko Sasaki
MAMasanori Akira
Masanori Akira
SAShinji Atagi
Shinji Atagi

22 August 2023 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
KNKenji Nakahama
Kenji Nakahama
MIMotohiro Izumi
Motohiro Izumi
NYNaoki Yoshimoto
Naoki Yoshimoto
MFMitsuru Fukui
Mitsuru Fukui
ASAkira Sugimoto
Akira Sugimoto
TKTomoya Kawaguchi
Tomoya Kawaguchi

25 April 2023 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KNKenji Nakahama
Kenji Nakahama
MIMotohiro Izumi
Motohiro Izumi
NYNaoki Yoshimoto
Naoki Yoshimoto
MFMitsuru Fukui
Mitsuru Fukui
ASAkira Sugimoto
Akira Sugimoto
TKTomoya Kawaguchi
Tomoya Kawaguchi
Background/Aim: There is no real-world data in an Asian population to investigate the difference between the outcome of immune-checkpoint inhibitor (ICI) monotherapy and combination therapy for non-small cell lung cancer (NSCLC) based on smoking status. In this study, we investigated the correlation between smoking status and the efficacy of ICI therapy for NSCLC patients. Patients and Methods: This multicentre retrospective study enrolled patients with recurrent or metastatic NSCLC who were treated using ICI therapy between December 2015 and July 2020. We analysed the objective response rate (ORR) of patients who received ICI monotherapy or combination therapy, based on smoking status using Fisher’s exact test, and progression-free survival (PFS) and overall survival (OS) based on smoking status using the Kaplan–Meier method, the log-rank test, and Cox proportional hazards model. Results: A total of 487 patients were included in the study. In the ICI monotherapy group, non-smokers showed significantly lower ORR and shorter PFS and OS than smokers (10% vs. 26%, p=0.002; median: 1.8 vs. 3.8 months, p<0.001; median: 8.0 vs. 15.4 months, p=0.026). In the ICI combination therapy group, non-smokers showed significantly longer OS than smokers (median: not reached vs. 26.3 months, p=0.045), and there was no significant difference in ORR and PFS between non-smokers and smokers (63% vs. 51%, p=0.43; median: 10.2 vs. 9.2 months, p=0.81). In the multivariate analysis of patients who received ICI combination therapy, the “non-smoker” status was not significantly associated with PFS [hazard ratio (HR)=1.31; 95% confidence interval (CI)=0.70-2.45, p=0.40] and OS (HR=0.40; 95% CI=0.14-1.13, p=0.083). Conclusion: Non-smokers showed worse outcomes than smokers with ICI monotherapy, but not with ICI combination therapy.

6 April 2023 in Cancer
Verified
Journal Article
Closed access
KNKenji Nakahama
Kenji Nakahama
MIMotohiro Izumi
Motohiro Izumi
NYNaoki Yoshimoto
Naoki Yoshimoto
MFMitsuru Fukui
Mitsuru Fukui
ASAkira Sugimoto
Akira Sugimoto
TKTomoya Kawaguchi
Tomoya Kawaguchi